Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis
- PMID: 24069133
- PMCID: PMC3775819
- DOI: 10.1371/journal.pone.0061361
Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis
Abstract
Background: The effect of interferon(IFN) in the management of hepatocellular carcinoma (HCC) remains controversial, and no clear recommendations have been proposed.
Objectives: To evaluate the effect and safety of IFN for HCC.
Methods: PubMed, OvidSP, and Cochrane Library were searched from their establishment date until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated and then subjected to meta-analysis.
Results: Thirteen randomized control trials (RCTs) involving 1344 patients were eligible for this study. When IFN was used as an adjuvant therapy for HCC patients after curative therapy, the meta-analysis showed that IFN reduced the 1-, 2-, 3-, 4-, and 5-year recurrence rates. Subgroup analysis showed that IFN reduced the 2-, 3-, 4-, and 5-year recurrence rates of hepatitis C viral (HCV)-related HCC. The effect of IFN for on hepatitis B virus(HBV)-related HCC patients could not be determined because of isufficient data. After surgical resection, adjuvant IFN therapy reduced the 4- and 5- recurrence rates. All studies reported that IFN could not improve the overall survival of HCV-realated HCC patients after curative therapies. Only one study showed that IFN was associated with better overall survival in HCC patients after curative therapy and subgroup of HCC patients after surgical resection. Thus, meta-analysis was not performed. Different treatment options were used as control to study the effect of IFN for intermediate and advanced HCC patients, thus meta-analysis was not appropriate. All included studies, except for one, reported that IFN treatment was well tolerated.
Conclusions: After curative therapies, adjuvant IFN reduced the recurrence of HCC. IFN did not improve the survival of HCV-related HCC patients after curative therapy. Whether IFN is effective for intermediate and advanced HCC patients could not be determined because of insufficient data. The toxicity of IFN was acceptable.
Conflict of interest statement
Similar articles
-
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3. Cochrane Database Syst Rev. 2015. PMID: 25620061 Free PMC article.
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD003617. doi: 10.1002/14651858.CD003617.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440791 Free PMC article.
-
Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 21;3(3):CD011645. doi: 10.1002/14651858.CD011645.pub2. Cochrane Database Syst Rev. 2017. PMID: 28321877 Free PMC article.
-
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221. Health Technol Assess. 2023. PMID: 38149643 Free PMC article.
Cited by
-
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.Oncotarget. 2016 Jun 7;7(23):34703-51. doi: 10.18632/oncotarget.9157. Oncotarget. 2016. PMID: 27167195 Free PMC article.
-
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.World J Gastroenterol. 2020 Nov 21;26(43):6770-6781. doi: 10.3748/wjg.v26.i43.6770. World J Gastroenterol. 2020. PMID: 33268960 Free PMC article. Review.
-
Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2015 Apr 7;21(13):3860-6. doi: 10.3748/wjg.v21.i13.3860. World J Gastroenterol. 2015. PMID: 25852270 Free PMC article. Review.
-
Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma.J Clin Transl Hepatol. 2022 Oct 28;10(5):783-785. doi: 10.14218/JCTH.2022.00229. Epub 2022 Jul 29. J Clin Transl Hepatol. 2022. PMID: 36304496 Free PMC article. No abstract available.
-
Advances in postoperative adjuvant therapy for primary liver cancer.World J Gastrointest Oncol. 2022 Sep 15;14(9):1604-1621. doi: 10.4251/wjgo.v14.i9.1604. World J Gastrointest Oncol. 2022. PMID: 36187393 Free PMC article. Review.
References
-
- Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global Cancer Statistics. CA CANCER J CLIN 61: 69–90. - PubMed
-
- El-Serag HB (2002) Hepatocellular carcinoma: An epidemiologic view. J Clin Gastrogenterol 35: S72–78. - PubMed
-
- Bruix J, Sherman M (2010) Management of hepatocellular carcinoma: An update. AASLD Practice Guidelines; Available: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%.... Accessed 2013 March 26.
-
- Nathan H, Schulick RD, Choti MA, Pawlik TM (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249: 799–805. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous